Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-221 PK and Safety Study in Healthy Males (Fed vs Fasted)
NCT02218346Phase 1Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Aug 2014
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of enasidenib in acute myeloid leukemia (AML) (2 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Pharmacokinetic (PK) profile of AG-221 at 504 hours and Incidence of adverse events at 105 days. Started Aug 2014; status: completed.
02
Drugs
enasidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02218346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02218346.